Background

Drug-eluting stents (DES) have demonstrated reduction of late loss (LL) and low target lesion revascularization (TLR) rates through an inhibitory effect on neointimal hyperplasia but might have a risk of late or very late stent thrombosis due to incomplete neointimal cover rate (NIC). Zotarolimus-eluting stent (ZES) and everolimus-eluting stent (EES) are next-negation DES that show higher LL than first-generation DES. However, differences in neointimal coverage between ZES and EES have been unclear.

Methods

Patients who received an implantation of a ZES ( n =30) or an EES ( n =30) were included in this study. Follow-up angiographic and angioscopic examination was performed at 372±65 days later in the ZES group and at 364±29 days later in the EES group. Yellow color grade (G0, G1, G2, G3) and coverage of stent by neointima (G0, G1, G2), and thrombus at the stented lesion (presence or absence) were evaluated by angioscopy. And we compared angioscopic view between ZES and EES.

Only gold members can continue reading. Log In or Register to continue

Share this:

• Click to share on Twitter (Opens in new window)
• Click to share on Facebook (Opens in new window)

Related

Related posts:

1. Left main coronary stenting in a non surgical octogenarian population: a possible approach
2. Shorter degradation period in BTI stents after porcine coronary artery implantation
3. The true incidence of atrial fibrillation after an atrial flutter ablation with continuous monitoring
4. Apical motion abnormality in patients undergoing transapical aortic valve replacement is frequent, yet spontaneously reversible

Stay updated, free articles. Join our Telegram channel

Join

Full access? Get Clinical Tree